Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of mangiferin in treating type II diabetes and vitro trial model thereof

A mangiferin aglycone and experimental model technology, applied in the fields of biopharmaceuticals and molecular biology, can solve the problems of elevated UCP2 expression, etc.

Inactive Publication Date: 2008-10-15
NANJING UNIV
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, hyperglycemia can also lead to increased expression of UCP2 in islets

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of mangiferin in treating type II diabetes and vitro trial model thereof
  • Application of mangiferin in treating type II diabetes and vitro trial model thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Embodiment 1 cell culture, incubation method

[0026] 293A cells were treated with DMEM high-glucose medium containing 10% fetal bovine serum in 95% air+5% CO 2 Cultured in a 60mm culture dish in a 60mm culture dish, when the cells covered about 80% of the culture dish, the supernatant was discarded, and 6 mL of DMEM high-glucose culture solution containing less than 2% fetal bovine serum and 6 μL of mangiferin aglycone liquid (concentration 10, 50, and 100 mM respectively, mangiferin was dissolved in DMSO, and the final concentration of DMSO was 0.1%), and the cells in the control group were incubated without mangiferin for 24 hours.

Embodiment 2

[0027] Example 2 Extraction, RT-PCR and real-time PCR of cellular RNA

[0028] After incubating for 24 hours, discard the supernatant, add 1mL Trizol to each petri dish, pipette thoroughly and transfer to a 1.5mL eppendoff tube, add 200μL chloroform, centrifuge at 13200rpm for 10 minutes, carefully pipette the supernatant into another clean 1.5mL eppendoff tube Add an equal volume of isopropanol, centrifuge at 13200 rpm for 10 minutes, discard the supernatant, wash the precipitate with 75% ethanol, and dry at room temperature. Then the precipitate was dissolved with 20 μL of DEPC water, and the concentration and purity of total RNA were detected by ultraviolet spectrometry.

[0029] 2μg RNA is used for reverse transcription, the reaction system is 20μL, containing 2μg RNA, 1mM dNTP, RNase inhibitor 1U / μL, Olig(dT)18 primer 2.5pmol / μL, AMV reverse transcriptase 0.5U / μL, mix gently Mix well, incubate at 42°C for 1 hour, at 70°C for 10 minutes, and place on ice for 2 minutes. T...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of norathyriol in treating type II diabetes, belonging to the technology field of biopharmaceuticals and molecular biology. After co-incubation of 293A cells and norathyriol for 24 hours, the expression level of uncoupling protein 2 (UCP2) coding gene in 293A cells is remarkably down-regulated. The invention discloses that the norathyriol can be used for inhibiting expression UCP2 gene in 293A cells and can be used for preparing drugs for preventing and treating type II diabetes; and proposes an in vitro test model for treating type II diabetes.

Description

1. Technical field [0001] The invention belongs to the technical fields of biopharmaceuticals and molecular biology, and specifically relates to the application of mangiferin in treating type II diabetes. 2. Background technology [0002] The etiology of type II diabetes mainly includes islet cell dysfunction and insulin resistance. Islet cell dysfunction is a complex phenomenon, including the loss of glucose sensing, leading to GSIS (glucose-stimulated insulin secretion) damage and so on. [0003] UCP2 (Uncoupling Protein 2, uncoupling protein 2) is a member of the uncoupling protein family and is a cationic carrier protein located on the inner membrane of mitochondria. It can cause leakage of protons, uncoupling of oxidative phosphorylation, reduction of ATP synthesis, and loss of energy in the form of heat. UCP2 is a negative regulator of insulin secretion. First, it mediates the proton leakage of the mitochondrial inner membrane, which has been demonstrated by a serie...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P3/10
Inventor 孙凌冰徐琛南发俊张昊张燕张辰宇谭仁祥项阳李佳李洪森邹季虹
Owner NANJING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com